HGEN News and Press, Humanigen Inc. From 09/15/20

Humanigen ( OTCQB:HGEN )   -1%   announced that it has commenced an underwritten public offering of 8M shares of common stock. More news on: Humanigen, Inc., , Healthcare stocks news Read more ...

Humanigen ( OTCQB:HGEN ) and Lonza announce a strategic collaboration to expand the manufacturing capacity for lenzilumab for COVID-19, in advance of potential Emergency Use Authorization in 2020 and subsequent commercialization. More news on: Humanigen, Inc., Healthcare stocks news, ...

The Independent Data Safety Monitoring Board (DSMB) has completed  pre-specified interim analysis for Humanigen's ( OTCQB:HGEN ) lead drug candidate lenzilumab Phase 3 trial for COVID-19 and recommended that the study continue unmodified. More news on: Humanigen, Inc., ...

Independent data safety monitoring board (DSMB) unanimously recommends trial continuation without modification after conducting pre-specified interim analysis for safety, futility, sample size and power Enrollment target of 300 patients expected to be completed this month ...

BURLINGAME, CA / ACCESSWIRE / September 4, 2020 / Humanigen, Inc. (OTCQB:HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm' with lenzilumab, the company's proprietary Humaneered ® ...

Reverse Split Facilitates Potential Uplisting to Nasdaq Humanigen, Inc. (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with lenzilumab, the company’...

Humanigen, Inc., (HGEN) (“Humanigen”), announced today that Cameron Durrant, MD, MBA, Chief Executive Officer, Dale Chappell, MD, MBA, Chief Scientific Officer, and Timothy Morris, Chief Operating and Financial Officer of Humanigen will present company overviews and business u...

Conference call and webcast scheduled for Thursday, September 3 at 11:00 a.m. EDT Humanigen, Inc. , (HGEN) (“Humanigen”), announced today that the Company will host an investor call and webcast to discuss the case-control lenzilumab data in COVID-19 patients publis...

Results from a 39-patient case-control study in hospitalized COVID-19 patients showed a significant treatment benefit from Humanigen's ( OTCQB:HGEN ) lenzilumab, its Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody. The data were just p...

80% reduction in relative risk of invasive mechanical ventilation and/or death in patients treated with lenzilumab compared to the control group Median time to resolution of acute respiratory distress syndrome (ARDS) reduced to one day for patients treated with lenzilumab versus ei...